ConductScience.org, home

Paper41354809

Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.

Ma X and 6 others. J Ovarian Res, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives. Papers, record 41354809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41354809

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.
PubMed
Journal
J Ovarian Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-01-25
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ma XXiao
2Qu LLinzhuo
3Wu QQunying
4Yu QQingqing
5Lin ZZhenhua
6Yang YYang
7Zhou XXianchun

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
Humans
Female
Immunotherapy

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
No.82160552the National Natural Science Foundation of ChinaPubMed
2024B001the Health Commission of Jilin ProvincePubMed
202501-202912the transverse projectPubMed

Source PubMed

Download CSV of grants

References151

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137802375Guizhi Fuling Formulation: A review on chemical constituents, quality control, pharmacokinetic studies, pharmacological properties, adverse reactions and clinical applications.J Ethnopharmacol2024https://conductscience.org/library/papers/37802375PubMed
233584699Dendritic Cell Vaccines in Ovarian Cancer.Front Immunol2020https://conductscience.org/library/papers/33584699PubMed
336331779Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.Drugs2022https://conductscience.org/library/papers/36331779PubMed
439817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
535816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022https://conductscience.org/library/papers/35816189PubMed
628039265Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.Clin Cancer Res2017https://conductscience.org/library/papers/28039265PubMed
732132244Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer.Microbiol Mol Biol Rev2020https://conductscience.org/library/papers/32132244PubMed
836902470Ovarian Cancer and Glutamine Metabolism.Int J Mol Sci2023https://conductscience.org/library/papers/36902470PubMed
938862154Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population.Int J Gynecol Cancer2024https://conductscience.org/library/papers/38862154PubMed
1029107691Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism.Biochem Biophys Res Commun2018https://conductscience.org/library/papers/29107691PubMed
1138388177
Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.
Int J Gynecol Cancer2024https://conductscience.org/library/papers/38388177PubMed
1239659585Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer.Theranostics2024https://conductscience.org/library/papers/39659585PubMed
1335264436Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.J Immunother Cancer2022https://conductscience.org/library/papers/35264436PubMed
1438777849The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.Cell Death Dis2024https://conductscience.org/library/papers/38777849PubMed
1534479871Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.Cancer Discov2022https://conductscience.org/library/papers/34479871PubMed
1638223825Ginsenoside 20(S)-Rg3 reduces KIF20A expression and promotes CDC25A proteasomal degradation in epithelial ovarian cancer.J Ginseng Res2024https://conductscience.org/library/papers/38223825PubMed
1740928736Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021.Int J Surg2026https://conductscience.org/library/papers/40928736PubMed
1819723649A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.Clin Cancer Res2009https://conductscience.org/library/papers/19723649PubMed
1934860006Cancer-Erythrocyte Hybrid Membrane-Camouflaged Magnetic Nanoparticles with Enhanced Photothermal-Immunotherapy for Ovarian Cancer.ACS Nano2021https://conductscience.org/library/papers/34860006PubMed
2038565643Short-chain fatty acids: linking diet, the microbiome and immunity.Nat Rev Immunol2024https://conductscience.org/library/papers/38565643PubMed

See all 151 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42957658Cell death-based treatment of ovarian cancer.Cell Death Dis2026https://conductscience.org/library/papers/42957658PubMed
42907928From cytoreduction to precision oncology: evolution of ovarian cancer therapy.J Ovarian Res2026https://conductscience.org/library/papers/42907928PubMed
42877886Stimulator of Interferon Genes (STING) Agonist-Loaded Copper-Based Nanoparticles for B7-H3 Blockade-Enhanced Chemodynamic-Immunotherapy of Ovarian Cancer.Int J Nanomedicine2026https://conductscience.org/library/papers/42877886PubMed
42819173Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications.Front Oncol2026https://conductscience.org/library/papers/42819173PubMed
42649936Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers (Basel)2026https://conductscience.org/library/papers/42649936PubMed
42590851Methotrexate Alters Nrf2/HO-1 Protein Expression and Intrinsic Apoptosis-Associated Protein Responses in OVCAR-3 Ovarian Cancer Cells: Differential Modulation by Antioxidant Compounds.J Biochem Mol Toxicol2026https://conductscience.org/library/papers/42590851PubMed
42587603Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.Diagnostics (Basel)2026https://conductscience.org/library/papers/42587603PubMed
42070192Deciphering the potential pathogenic mechanisms of 3-BHA in ovarian cancer through integrated bioinformatics and machine learning strategies.Discov Oncol2026https://conductscience.org/library/papers/42070192PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41354809

GET https://conductscience.org/api/papers/v1/41354809/references?page=2